RESP.ST Respiratorius AB

Healthcare Real Estate Management & Development Stockholm Exchange
2.17 SEK
Close of Nov 3, 2026
1.19 3.54
Market cap
SEK 17.1M
P/E
-
P/B
0.39x
ROE
-25.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is RESP.ST undervalued?

Graham number

The Graham number of Respiratorius AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Respiratorius AB fundamental analysis

No fundamental analysis for Respiratorius AB yet.

Respiratorius AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Respiratorius AB

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. Its products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. The company was incorporated in 1998 and is based in Lund, Sweden.

Full company profile